Panobinostat in adults with H3 K27M-mutant diffuse midline glioma: a single-center experience.

Byran J NethSamantha N BalakrishnanIvan D CarabenciovJoon H UhmDavid J DanielsSani H KizilbashMichael W Ruff

Published in: Journal of neuro-oncology (2022)

This is the first report of clinical outcomes of panobinostat in adults with H3 K27M-mutant DMG. We showed that it is well-tolerated at the dosage schedule that we describe, with no serious adverse effects throughout the study period.

Keyphrases

histone deacetylase
wild type